Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease

European Journal of Pediatrics

Volumn 163, Issue 4-5, 2004, Pages 229-233

  Jibiki, Toshiaki ^a   Terai, Masaru ^b   Kurosaki, Tomomichi ^a   Nakajima, Hiromichi ^a   Suzuki, Kazuhiro ^c   Inomata, Hiroaki ^c   Terashima, Itaru ^c   Honda, Takafumi ^b   Yasukawa, Kumi ^b   Hamada, Hiromichi ^b   Kohno, Yoichi ^b  

^a Chiba Municipal Hospital   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Coronary artery aneurysms; Dexamethasone; Intravenous immune globulin; Kawasaki disease; Vascular endothelial growth factor

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; DEXAMETHASONE; HEPARIN; IMMUNOGLOBULIN; VASCULOTROPIN;

ARTICLE; CHILD; CLINICAL TRIAL; CORONARY ARTERY ANEURYSM; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GLUCOSURIA; HEMATOCRIT; HUMAN; HYPERTENSION; INFANT; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANK SUM TEST; THROMBOCYTE COUNT; THROMBOEMBOLISM; TREATMENT OUTCOME;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; CHILD, PRESCHOOL; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 2442693951     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-003-1386-5     Document Type: Article

References (20)

1. Chrousos GP, Margioris AN (2000) Adrenocorticosteroids and adrenocortical antagonists. In: Katzung BG (ed) Basic and clinical pharmacology. Lange Medical Books/McGraw-Hill, New York, pp 660-678
2. Couser RJ, Ferrara TB, Falde B, Johnson K, Schilling CG, Hoekstra RE (1992) Effectiveness of dexamethasone in preventing extubation failure in preterm infant at increased risk for airway edema. J Pediatr 121: 591-596
3. Hashino K, Ishii M, Iemura M, Akagi T, Kato H (2001) Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 43: 211-217
4. Ikeda Y, Carson BS, Lauer JA, Long DM (1993) Therapeutic effects of local delivery of dexamethasone on experimental brain tumors and peritoneal brain edema. J Neurosurg 79: 716-721
5. Japan Kawasaki Disease Research Committee (1984) 1984 Diagnostic guidelines of Kawasaki disease, 4th rev. edn. Japan Kawasaki Disease Research Committee, Tokyo
6. Kawasaki T (1967) Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children: clinical observations of 50 cases (in Japanese). Arerugi 16: 178-222
7. Koedam JA, Smink JJ, van Buul-Offers SC (2002) Glucocorticoids inhibit vascular endothelial growth factor expression in growth plate chondrocytes. Mol Cell Endocrinol 197: 35-44
8. Lassus P, Nupponen I, Kari A, Pohjavuori M, Andersson S (2002) Early postnatal dexamethasone decreases hepatocyte growth factor in tracheal aspirate fluid from premature infants. Pediatrics 110: 768-771
9. Maeno N, Takei S, Masuda K, Akaike H, Matsuo K, Kitajima I, Maruyama I, Miyata K (1998) Increased serum levels of vascular endothelial growth factor in Kawasaki disease. Pediatr Res 44: 596-599
10. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE , Fulton DR, Glode MP, Mason WH, Meissner HC, Rowley AH, Shulman ST, Reddy V, Sundel RP, Wiggins JW, Colton T, Melish ME, Rosen FS (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324: 1633-1639
11. Nonaka Z, Maekawa K, Okabe T, Eto Y, Kubo M (1995) Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. In: Kato H (ed) Kawasaki disease. Proceedings of the 5th International Kawasaki Disease Symposium. Elsvier Science BV, Amsterdam, pp 328-331
12. Ohno T, Yuge T, Kariyazono H, Igarashi H, Joh-o K, Kinugawa N, Kusuhara K, Hara T (2002) Serum hepatocyte growth factor combined with vascular endothelial growth factor as a predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr 161: 105-111
13. Sato N, Sugimura T, Akagi T, Yamakawa R, Hashino K, Eto G, lemura M, Ishii M, Kato H (1999) Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatr Int 41: 1-7
14. Shinohara M, Sone K, Tomomasa T, Morikawa A (1999) Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 135: 465-469
15. Shulman ST, De Inocencio J, Hirsch R (1995) Kawasaki disease. Pediatr Clin North Am 42: 1205-1222
16. Sundel RP, Baker AL, Fulton DR, Newberger JW (2003) Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 142: 611-616
17. Terai M, Shulman ST (1997) Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent on salicylate dose. J Pediatr 131: 888-893
18. Terai M, Honda T, Yasukawa K, Higashi K, Hamada H, Kohno Y (2003) Prognostic impact of vascular leakage in acute Kawasaki disease. Circulation 108: 325-330
19. Wright DA, Newburger JW, Baker A, Sundel RP (1996) Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 128: 146-149
20. Yasukawa K, Terai M, Shulman ST, Toyozaki T, Yajima S, Kohno Y, Rowley AH (2002) Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease. Circulation 105: 766-769